Email updates

Keep up to date with the latest news and content from Thyroid Research and BioMed Central.

This article is part of the supplement: European comments on Medullary Thyroid Cancer Management Guidelines of the American Thyroid Association

Open Access Review

The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association

Laura Fugazzola*, Simone De Leo and Michela Perrino

Author Affiliations

Department of Clinical Sciences & Community Health , University of Milan; Endocrine Unit, Fondazione IRCCS Ca’ Granda, Via F. Sforza, 35, 20122 Milan, Italy

For all author emails, please log on.

Thyroid Research 2013, 6(Suppl 1):S8  doi:10.1186/1756-6614-6-S1-S8

Published: 14 March 2013

Abstract

In the 9th ETA-CRN Meeting (September 2009, Lisbon) some recommendations from the American Thyroid Association (ATA) guidelines for the management of medullary thyroid cancer (MTC) were discussed by an European Panel of Experts (EPE). Among the 12 ATA recommendations related to hereditary MTC and to the optimal range of RET mutations to be tested (recommendations 1-5 and 9-15), 7 were shared and 5 were not shared by the EPE. In the present paper, the related comments and suggestions will be reported and discussed.